Pfizer's Big Year
This article was originally published in RPM Report
Executive Summary
Pfizer expects as many as six new drug approvals in 2006. That will go a long way towards helping increase the overall new drug approval total for the year. But it doesn't mean Pfizer's R&D engine is running better than anyone else's.
You may also be interested in...
US HHS Nominee Becerra Treading Carefully On ‘March In’ Rights
Past support for so-called ‘march in’ rights is a red flag for biopharma innovators, but after two days of confirmation hearings, industry can be somewhat reassured.
US FDA’s Big Transition: Not The Commissioner – The Drug Center
It remains uncertain whether Acting Commissioner Woodcock will be nominated for the post. Regardless, the drug center she has run for most of three decades is going to have to adjust to new management.
A New Start: President Biden Visits Pfizer
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: